European luxury goods concept stocks saw the largest weekly increase since 2012.
On Friday, September 27, the STOXX 600 index's personal and household goods index closed up by 1.77%, rising for the fifth consecutive trading day, with a total surge of 9.38% for the week. Data shows that among the components, Moncler rose by 10.91% on Friday, Burberry rose by 6.96%, Kering Group rose by 6.34%, Ubisoft Entertainment rose by 5.94%, Hugo Boss rose by 5.45%, ranking fifth in performance, LVMH Group rose by 3.67%, ranking ninth in terms of increase, while L'Oreal fell by 0.66% - posting the largest decline among the three components that fell. In the "Eleven Apostles of European Stocks," Novo-Nordisk fell by 4.59%, and L'Oreal fell...
Perspective Draws Buy at Truist on Radiopharma Potential
MITEM PHARMA Acquires Worldwide Rights to DESFERAL (Deferoxamine) With the Backing of TECHLIFE CAPITAL and MACSF
Citi Sticks to Its Hold Rating for Novartis AG (NOVN)
Novartis AG Falls Tuesday, Underperforms Market
Generate:Biomedicines Announces Multi-Target Collaboration With Novartis to Discover and Develop Protein Therapeutics With Generative AI
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
Prostate cancer RLT therapy has a promising future! Pluvicto, a subsidiary of Novartis AG (NVS.US), is expected to become a leader.
The radioactive ligand therapy (RLT) market is expected to experience significant growth by 2030, and Novartis AG's RLT product, Pluvicto, is expected to capture the largest share in the field of prostate cancer therapy.
Novartis' Pluvicto Expected to Dominate Prostate Cancer Radiopharmaceutical Market
Sharp Sword! The FTC sues three major pharmaceutical 'middlemen', vowing to correct the distorted chain of interests.
①The USA FTC announced on its official website that it has filed a lawsuit against three major pharmaceutical benefit managers and their affiliated organizations, accusing them of engaging in anti-competitive and unfair rebate practices; ② The FTC also "explicitly stated" in the declaration that it is deeply concerned about the roles played by Eli Lilly, Novo-Nordisk, and Sanofi, insulin pharmaceutical companies, and may suggest in future enforcement actions to prosecute these pharmaceutical manufacturers.
How Critical Demand for Metastatic Breast Cancer Therapies Is Producing a Multi-Billion Dollar Opportunity for Biotechs
Cancer Research Sees Major Boost as New Breakthroughs Emerge From Key Oncology Players
Will Rate Cuts Boost the Stock Market? A Global Equity Investment Guide
6-K: Explanatory Note
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Weight Loss Drug Pricing Under Fire With Pills on the Horizon
The CEO of Novartis said that Novartis will not join the weight loss drug craze.
Vas Narasimhan, CEO of Swiss pharmaceutical giant Novartis AG, said on Wednesday that the company has no plans to enter the "craze" of weight loss drugs, but would rather focus on areas where it can establish a "unique position". Vas Narasimhan said in an interview with the media that the company is studying treatment methods for the secondary effects of weight loss drugs, but it does not intend to directly compete with dominant obesity pharmaceutical companies such as Novo Nordisk A/S and Eli Lilly and Co. The stimulating effect of a drug refers to the non-direct therapeutic effect produced by a drug or drug treatment. In pharmacology...
Express News | Novartis Announced New Data From ALITHIOS Open-label Extension Study, Showing First-line Kesimpta (Ofatumumab) Treatment For Up To Six Years Led To Less Disability And Disease Progression In Recently Diagnosed And Treatment-naïve Relapsing Multiple...
Goldman Sachs Remains a Hold on Novartis AG (NOVN)